Trial · NCT00333814
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
NCT00333814, Phase 2, Phase 3, Completed, Allergan; results first posted 2011-04-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis. Trials, record NCT00333814. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00333814
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
- NCT number
- NCT00333814
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 229 participants, actual
- Lead sponsor
- Allergan
- Conditions
- Intermediate Uveitis, Posterior Uveitis
- Interventions
- Dexamethasone, dexamethasone, Sham injection
- First posted
- 2006-06-06
- Last updated
- 2011-04-14
- Results first posted
- 2011-04-14
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero | Week 8 | Percentage of patients with Vitreous Haze Score of Zero at Week 8. Score is based on standardized scale of 0 to +4 where 0 equals no inflammation and +4 equals optic nerve head not visible (severe). |
| Other | Percentage of Patients With at Least a 15-Letter Improvement in Best Corrected Visual Acuity (BCVA) | Week 8 | Percentage of Patients with at least a 15-letter improvement in BCVA at Week 8 from Baseline. BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity). An improvement in the number of letters read means that the vision has improved. |
| Other | Percentage of Patients With at Least a 10-Point Improvement in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25)Score | Week 8 | Percentage of patients with at least a 10-Point Improvement in the NEI-VFQ-25 over-all composite score at Week 8 from Baseline. The NEI-VFQ-25 consists of 25 vision-targeted questions plus one general health question resulting in a score of 0-100 (100 represents best functionality). |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero | Week 8 | Intent to Treat | Percentage of Patients | NUMBER |
| OTHER_PRE_SPECIFIED | Percentage of Patients With at Least a 15-Letter Improvement in Best Corrected Visual Acuity (BCVA) | Week 8 | Intent to Treat | Percentage of Patients | NUMBER |
| OTHER_PRE_SPECIFIED | Percentage of Patients With at Least a 10-Point Improvement in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25)Score | Week 8 | Intent to Treat | Percentage of Patients | NUMBER |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero | Dexamethasone 350 µg | 35.5 | Percentage of Patients | ||
| Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero | Dexamethasone 700 µg | 46.8 | Percentage of Patients | ||
| Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero | Sham | 11.8 | Percentage of Patients | ||
| Percentage of Patients With at Least a 15-Letter Improvement in Best Corrected Visual Acuity (BCVA) | Dexamethasone 350 µg | 39.5 | Percentage of Patients | ||
| Percentage of Patients With at Least a 15-Letter Improvement in Best Corrected Visual Acuity (BCVA) | Dexamethasone 700 µg | 42.9 | Percentage of Patients | ||
| Percentage of Patients With at Least a 15-Letter Improvement in Best Corrected Visual Acuity (BCVA) | Sham | 6.6 | Percentage of Patients | ||
| Percentage of Patients With at Least a 10-Point Improvement in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25)Score | Dexamethasone 350 µg | 40.8 | Percentage of Patients | ||
| Percentage of Patients With at Least a 10-Point Improvement in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25)Score | Dexamethasone 700 µg | 50.7 | Percentage of Patients | ||
| Percentage of Patients With at Least a 10-Point Improvement in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25)Score | Sham | 15.9 | Percentage of Patients |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dexamethasone 350 µg | 76 | |
| Overall Study | STARTED | Dexamethasone 700 µg | 77 | |
| Overall Study | STARTED | Sham | 76 | |
| Overall Study | COMPLETED | Dexamethasone 350 µg | 73 | |
| Overall Study | COMPLETED | Dexamethasone 700 µg | 73 | |
| Overall Study | COMPLETED | Sham | 71 | |
| Overall Study | NOT COMPLETED | Dexamethasone 350 µg | 3 | |
| Overall Study | NOT COMPLETED | Dexamethasone 700 µg | 4 | |
| Overall Study | NOT COMPLETED | Sham | 5 |
Source ClinicalTrials.gov
Adverse events114
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival haemorrhage | Eye disorders | Dexamethasone 350 µg | 13 | 74 | |
| other | Conjunctival haemorrhage | Eye disorders | Dexamethasone 700 µg | 23 | 76 | |
| other | Conjunctival haemorrhage | Eye disorders | Sham | 16 | 75 | |
| other | Intraocular pressure increased | Investigations | Dexamethasone 350 µg | 17 | 74 | |
| other | Intraocular pressure increased | Investigations | Dexamethasone 700 µg | 19 | 76 | |
| other | Intraocular pressure increased | Investigations | Sham | 5 | 75 | |
| other | Eye Pain | Eye disorders | Dexamethasone 350 µg | 8 | 74 | |
| other | Eye Pain | Eye disorders | Dexamethasone 700 µg | 11 | 76 | |
| other | Eye Pain | Eye disorders | Sham | 10 | 75 | |
| other | Iridocyclitis | Eye disorders | Dexamethasone 350 µg | 2 | 74 |
1 to 10 of 114Source ClinicalTrials.gov
See all 114 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dexamethasone 350 µg | ||
| Total, all-cause mortality | Dexamethasone 700 µg | ||
| Total, all-cause mortality | Sham | ||
| Total, other adverse events | Dexamethasone 350 µg | 58 | 74 |
| Total, other adverse events | Dexamethasone 700 µg | 61 | 76 |
| Total, other adverse events | Sham | 51 | 75 |
| Total, serious adverse events | Dexamethasone 350 µg | 6 | 74 |
| Total, serious adverse events | Dexamethasone 700 µg | 7 | 76 |
| Total, serious adverse events | Sham | 5 | 75 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00333814
GET https://conductscience.org/api/trials/v1/NCT00333814/events?page=2